Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

MM24: Updated Data and Guidelines on COVID-19 Treatments

In this presentation, Professor Sharon Lewin discusses the FDA approval of remdesivir and the data from the ACTT-1 and WHO SOLIDARITY trials.
Sharon R. Lewin, AO, FRACP, PhD, FAHMS
Released: October 30, 2020

Information on this Educational Activity

Faculty

Sharon R. Lewin, AO, FRACP, PhD, FAHMS

Director, The Peter Doherty Institute for Infection and Immunity
Professor of Infectious Diseases
Faculty Medicine Dentistry and Health Sciences
University of Melbourne and Royal Melbourne Hospital
Consultant Infectious Diseases Physician
Department of Infectious Diseases
Royal Melbourne Hospital and Alfred Hospital
Melbourne, Australia

Sharon Lewin, AO, FRACP, PhD, FAAHMS, has disclosed that she has received consulting fees from AbbVie, Gilead Sciences, and ViiV Healthcare; funds for research support from Leidos; and other financial or material support from Gilead Sciences, Merck, and ViiV Healthcare.

Program Medium

This program has been made available online.

Related Content

From Clinical Care Options (CCO) and Dr. Dalilah Restrepo: guidance on use of the recombinant zoster vaccine (RZV) to prevent shingles complications

person default Dalilah Restrepo, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: November 10, 2021 Expired: November 9, 2022

Download key slides on guidance and CDC recommendations on vaccination to prevent shingles and its complications in the COVID-19 era.

person default Dalilah Restrepo, MD Released: November 10, 2021

Expert commentary on incorporating lessons from the COVID-19 pandemic into improving HCV care among vulnerable populations, from Dr. Gregory Dore and Clinical Care Options (CCO)

Gregory Dore, MBBS, PhD, FRACP, MPH Released: November 8, 2021

Download slides reviewing the latest data and guidance on COVID-19 treatments, including authorized and investigational agents, from Clinical Care Options (CCO)

Arthur Kim, MD Sharon R. Lewin, AO, FRACP, PhD, FAHMS Renslow Sherer, MD Released: November 4, 2021
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Educational grant provided by
Gilead Sciences, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue